Center of scientific-technological forecasting in the University: instruments and methodology

Kurakova Natalia, Moscow International Business School MIRBIS



Main myth and risk of innovative field in Russia

September, 2011: Igor Agamirzyan, general director RBC: «The myth of Russian innovative field – preservation of global leadership in fundamental science»

Rating of science of Russian Federation by the end of 2011 (ESI)

- Citations Per Paper -126 place in the world rating
- Highly Cited Papers- 1,04%, Hot Papers 1,44%


Basics of politics of Russian Federation in the field of science and technologies development

Strategic target: «Russian Federation reaching a global level in research and developments by 2020 year... and developing sixth technological way in Russian Federation»

Approved by the President D.Medvedev

11 January 2012 year

NANOSCIENCE&NANOTECHNOLOGY: RUSSIA,ISRAIL,USA (1981-2010)



In how many research fronts of world science does ESI invest?

1st February 2012 : Global science is resented by:

- 7527 research fronts :
- 1724 Clinical medicine (320-oncology)
- **1263** Chemistry
- **694** Physics
- 612 Biology & biochemistry
- 401 Molecular Biology
- 289 Pharmacology & Toxicology
- 269 Mathematics

How many research fronts are developed with participation of Russian researchers?

RESEARCH FRONTS RANKINGS IN CLINICAL MEDICINE								
Sorted by: Citations SORTAGAN								
1 - 20 (of 1724) [1 2 3 4 5 6 7 8 9 10]						Page 1 of 87		
	Vie	ew	Fronts	Papers	Citations	Citations Per Paper	Mean Year	
1			REGULATORY T CELL CD4(+)CD25(-)FOXP3(-) T CELL TH17 CELL SELF-INDUCTION; FOLLICULAR B HELPER T CELLS; T FOLLICULAR HELPER (T-FH) CELLS; T FOLLICULAR HELPER CELLS DIFFERENTIATE; FOLLICULAR HELPER T CELLS	38	13,316	350.42	2007.8	
2			HUMAN INDUCED PLURIPOTENT STEM CELLS; GERMLINE-COMPETENT INDUCED PLURIPOTENT STEM CELLS; INDUCED PLURIPOTENT STEM CELL LINES DERIVED; HUMAN SOMATIC CELLS; ADULT HUMAN FIBROBLASTS	10	11,515	1151.50	2007.4	
3			NOVEL TYPE 2 DIABETES RISK LOCUS MTNR1B DETERMINE BETA-CELL FUNCTION; TWELVE TYPE 2 DIABETES SUSCEPTIBILITY LOCI TYPE 2 DIABETES GENES CDKAL1; TYPE 2 DIABETES MELLITUS; TRANSCRIPTION FACTOR 7-LIKE 2 (TCF7L2) GENE CONFERS RISK	46	10,759	233.89	2007.9	
4		ш	COLON CANCER STEM CELLS DICTATE TUMOR GROWTH; DRUG-SELECTED HUMAN LUNG CANCER STEM CELLS; CANCER STEM CELLS DETERMINE TUMOR GROWTH; HUMAN COLORECTAL CANCER STEM CELLS	38	9,952	261.89	2007.5	
5			METASTATIC RENAL CELL CARCINOMA EVEROLIMUS FINAL RESULTS-PROGNOSTIC FACTOR ANALYSIS; BEVACIZUMAB-REFRACTORY METASTATIC RENAL CELL CARCINOMA; METASTATIC RENAL CELL CARCINOMA (AVOREN); SORAFENIB-REFRACTORY METASTATIC RENAL CELL CARCINOMA;	30	8,992	299.73	2008.2	
6			CHEMOTHERAPY-REFRACTORY METASTATIC COLORECTAL CANCER TREATED; EPIDERMAL GROWTH FACTOR RECEPTOR EXPRESSING METASTATIC COLORECTAL CANCER PATIENTS TREATED; 13 WILD-TYPE METASTATIC COLORECTAL CANCER; CHEMOTHERAPY REFRACTORY COLORECTAL CANCER PATIENTS	39	8,584	220.10	2008.2	
7			CROHN'S DISEASE RISK LOCI; CROHN'S DISEASE IDENTIFIES PREVIOUSLY UNKNOWN DISEASE LOCI; CROHN'S DISEASE ASSOCIATED ATG16L1 VARIANT; QUEBEC FOUNDER POPULATION IDENTIFIES MULTIPLE VALIDATED DISEASE LOCI; CROHN'S DISEASE SUSCEPTIBILITY	36	8,437	234.36	2007.4	
8		ш	LOW HUMAN BETA-DEFENSIN 2 GENE COPY NUMBER; HIGH-RESOLUTION COPY NUMBER VARIATION DETECTION; ACCURATELY MAP COPY NUMBER VARIATION; SYSTEMIC LUPUS ERYTHEMATOSUS IDENTIFIES SUSCEPTIBILITY VARIANTS; COMMON COPY NUMBER POLYMORPHISMS	31	8,428	271.87	2007.2	
9		ш	DRUG-ELUTING CORONARY STENTS; DRUG-ELUTING STENTS; LATE DRUG-ELUTING STENT THROMBOSIS; 14 TRIALS COMPARING SIROLIMUS-ELUTING STENTS; PACLITAXEL-ELUTING CORONARY STENTS	28	8,314	296.93	2006.8	
10		ш	NODE-NEGATIVE BREAST CANCER PATIENT 76-GENE PROGNOSTIC SIGNATURE STRONG TIME DEPENDENCE TRANSBIG MULTICENTER INDEPENDENT VALIDATION SERIES; CONSERVATIVELY MANAGED TRIPLE NEGATIVE EARLY-STAGE BREAST CANCER; TRIPLE NEGATIVE BREAST CANCER	42	8,260	196.67	2007.3	
11			HUMAN EMBRYONIC STEM CELLS; PLURIPOTENT EMBRYONIC STEM CELLS; MURINE EMBRYONIC STEM CELLS; CHROMATIN PROTEINS STEM CELLS; POLYCOMB SILENCERS CONTROL CELL FATE	17	7,502	441.29	2006.8	
		ш	CHRONIC HEPATITIS B VIRUS INFECTION FOLLOWING RITUXIMAB ADMINISTRATION; HEPATITIS B E ANTIGEN-POSITIVE CHRONIC HEPATITIS B; LAMIVUDINE-REFRACTORY HEPATITIS B VIRUS	49	6,922	141.27	2008.1	
отово	TOBO				Онтернет Защищенный	режим: вкл.	√	


Participation of Russia in research fronts of global science?

- ■Physics 84 (14,92%)
- ■Clinical medicine 41 (2,62%)
- Biology & biochemistry -10 (1,71%)
- ■Chemistry –18 (1,62%)
- •Mathematics 0

Quantity Competencies in counries (SciVal Spotlight)

Quantity competencies	Russia	China	Brazil	India
Competencies	90	773	96	130
Distinctive competencies	51	702	74	105
Emerging competencies	39	71	22	25

Ratio estimation of being rated in research world trends




It is possible to define perspective fields for research and potential for financing projects in this field

SciVal: HARVARD UNIVERCITY (2005-2009)

)

- Clusters 563
- Distinctive Competence 72



Clusters, in which Russian physicians are the leaders (6 of 28 clusters RAMS)

Compotonov	Authors at this institution	Keywords	Dissiplines	Articles published	
Competency			Disciplines	worldwide	institution
EC #2	Rzhaninova A.A.;	protein kinase; sodium	Clinical Cancer Research; Biomaterials	1,255	14
<u>DC #5</u>	Khrichkova T.Y.;	bone marrow; colony- stimulating factor; granulocytic CSF	· ·	958	41
EC #17	Zvonkov E.E.;	B-cell lymphoma; median follow-up; stromal cells	Leukemia; Clinical Cancer Research	460	5
EC #18	Savchenko A.A.;	DXIDASE ACTIVATION.	Immunology; Oncology	389	5
EC #19	Preobrazhenskaya M. N.: Globa A. G.	IVIENGEIEEV	Russian Chemistry Research; Clinical Cancer Research	303	5
EC #24	Velko N.N.; Konorova III. · Frshova F S	apoptosis repressor;	Clinical Cancer Research; Immunology	242	5


Russian Oncology Scientific center after N.H.Blohina

			· · ·	Articles published	
Competency	Authors at this institution	Keywords	Disciplines	worldwide	institution
EC #1	Zaridze D.G.; Zaridze D.G.; Shangina O.V.	cell carcinoma; alcohol consumption; odds ratio	Clinical Cancer Research; Medical Screening & Epidemiology; Occupational Health	1,665	33
EC #2	Golovina D.A. Volgareva	cervical cancer; squamous intraepithelial; intraepithelial lesions	Clinical Cancer Research; Pathology	1,012	14
EC #3		cancer cells; breast cancer; cell proliferation	Clinical Cancer Research	706	14
EC #4	Kushlinskii N.E.; Delektorskaya V.V.; Gershteĭn E.S.	cell carcinoma; squamous cell; oral squamous	Periodontology; Urology; Headache	677	5
EC #5	Kobliakov V.A.; Bolotina N.A.; Evteev V.A.	transcription factor; cell cycle; cell proliferation	Toxicology Applied Pharmacology; Clinical Cancer Research	524	4
EC #6		smooth muscle; ± μM; light chain	Molecular Cell Biology; Clinical Cancer Research	690	8

IMPACT RELATIVE TO SUBJECT AREA (WOS). Clinical medicine

- «МИРОВОЙ УРОВЕНЬ»: IMPACT RELATIVE TO SUBJECT AREA =1
- Rheumatology 3,84
- Oncology 3,34
- Urology- 1,42
- Radiology, Nuclear Medicine & Medical Imaging- 1,34
- Cardiac & Cardiovascular Systems 0,11
- Dermatology- 0
- Integrative & Complementary Medicine- 0

IMPACT RELATIVE TO SUBJECT AREA (WOS): oncology, infection diseases, cardiac &cardiovascular systems



THANK YOU!

KURAKOVA NATALIA



Moscow International Business

- kpo@mirbis.ru,
- idmz@mednet.ru